NASDAQ:DRMA Dermata Therapeutics (DRMA) Stock Forecast, Price & News $1.07 -0.01 (-0.93%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$1.06▼$1.0850-Day Range$1.01▼$1.5952-Week Range$0.94▼$13.12Volume12,394 shsAverage Volume306,601 shsMarket Capitalization$3.41 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Dermata Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside273.8% Upside$4.00 Price TargetShort InterestHealthy0.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 stars 3.5 Analyst's Opinion Consensus RatingDermata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Dermata Therapeutics has a forecasted upside of 273.8% from its current price of $1.07.Amount of Analyst CoverageDermata Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.02% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently decreased by 95.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDermata Therapeutics does not currently pay a dividend.Dividend GrowthDermata Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRMA. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.40% of the stock of Dermata Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.78% of the stock of Dermata Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Dermata Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dermata Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermata Therapeutics has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dermata Therapeutics (NASDAQ:DRMA) StockDermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More DRMA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRMA Stock News HeadlinesAugust 31, 2023 | finance.yahoo.comDermata to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 11, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsSeptember 26, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.June 27, 2023 | finance.yahoo.comDermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe AcneJune 13, 2023 | finance.yahoo.comDermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETJune 8, 2023 | finance.yahoo.comJournal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne ResultsJune 8, 2023 | finanznachrichten.deDermata Therapeutics: Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne ResultsMay 26, 2023 | finance.yahoo.comDermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesSeptember 26, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.May 24, 2023 | finance.yahoo.comDermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesMay 24, 2023 | msn.comDermata Therapeutics announces $1.8M offering priced ATMMay 24, 2023 | finance.yahoo.comDermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesMay 12, 2023 | marketwatch.comDermata Therapeutics Shares Rally Premarket on DMT310 Update >DRMAMay 11, 2023 | seekingalpha.comDermata Therapeutics GAAP EPS of -$2.27May 11, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 9, 2023 | proactiveinvestors.comDermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studiesApril 21, 2023 | finance.yahoo.comDermata (DRMA) Gains on Positive FDA Response for Acne CandidateApril 20, 2023 | finanznachrichten.deDermata Therapeutics: Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting PackageApril 20, 2023 | msn.comDermata climbs ~28% after update on acne candidateApril 20, 2023 | finance.yahoo.comDermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting PackageMarch 31, 2023 | benzinga.comDermata Therapeutics Inc (DRMA) has risen 6.40% Wednesday In Premarket TradingMarch 26, 2023 | benzinga.comDermata Therapeutics Stock (NASDAQ:DRMA), Guidance and ForecastMarch 24, 2023 | markets.businessinsider.comWhy Is Allarity Therapeutics (ALLR) Stock Down 23% Today?March 20, 2023 | finance.yahoo.comDermata Therapeutics Announces Closing of $5.0 Million Public OfferingMarch 20, 2023 | finance.yahoo.comDermata Therapeutics Announces Closing of $5.0 Million Public OfferingMarch 16, 2023 | marketwatch.comDermata Therapeutics Up 24% After Boosting Size of OfferingMarch 16, 2023 | finance.yahoo.comDermata Therapeutics Announces Pricing of $5.0 Million Public OfferingSee More Headlines Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DRMA Company Calendar Last Earnings8/10/2023Today9/26/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRMA CUSIPN/A CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+273.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-108.55% Return on Assets-94.75% Debt Debt-to-Equity RatioN/A Current Ratio12.76 Quick Ratio12.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.82 per share Price / Book0.14Miscellaneous Outstanding Shares3,190,000Free Float2,889,000Market Cap$3.41 million OptionableNot Optionable Beta0.45 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Gerald T. Proehl (Age 64)Founder, Pres, CEO & Chairman Comp: $352.92kMr. David F. Hale (Age 74)Co-Founder & Lead Independent Director Comp: $18.12kMs. Kyri K. Van Hoose CPA (Age 44)M.B.A., Sr. VP & CFO Comp: $328.75kDr. Christopher J. Nardo M.P.H. (Age 58)Ph.D., Sr. VP & Chief Devel. Officer Comp: $329.92kMr. Sean ProehlSr. Director of Legal & Bus. Devel.Dr. Maria Bedoya Toro Munera M.B.A. (Age 71)Ph.D., Sr. VP of Regulatory Affairs & Quality Assurance More ExecutivesKey CompetitorsAgile TherapeuticsNASDAQ:AGRXAditxtNASDAQ:ADTXAridis PharmaceuticalsNASDAQ:ARDSBellicum PharmaceuticalsNASDAQ:BLCMEvoke PharmaNASDAQ:EVOKView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 17,190 shares on 8/15/2023Ownership: 0.539%Acadian Asset Management LLCBought 56,285 shares on 8/7/2023Ownership: 2.405%Virtu Financial LLCBought 32,105 shares on 7/27/2023Ownership: 1.372%View All Institutional Transactions DRMA Stock - Frequently Asked Questions Should I buy or sell Dermata Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermata Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRMA shares. View DRMA analyst ratings or view top-rated stocks. What is Dermata Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued 12-month price objectives for Dermata Therapeutics' shares. Their DRMA share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 273.8% from the stock's current price. View analysts price targets for DRMA or view top-rated stocks among Wall Street analysts. How have DRMA shares performed in 2023? Dermata Therapeutics' stock was trading at $6.5440 at the beginning of 2023. Since then, DRMA stock has decreased by 83.6% and is now trading at $1.07. View the best growth stocks for 2023 here. Are investors shorting Dermata Therapeutics? Dermata Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 600 shares, a decrease of 95.8% from the August 15th total of 14,400 shares. Based on an average daily trading volume, of 175,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company's shares are sold short. View Dermata Therapeutics' Short Interest. When is Dermata Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our DRMA earnings forecast. How were Dermata Therapeutics' earnings last quarter? Dermata Therapeutics, Inc. (NASDAQ:DRMA) issued its earnings results on Thursday, August, 10th. The company reported ($0.63) earnings per share for the quarter. When did Dermata Therapeutics' stock split? Dermata Therapeutics's stock reverse split on Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Dermata Therapeutics IPO? (DRMA) raised $18 million in an IPO on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share. What is Dermata Therapeutics' stock symbol? Dermata Therapeutics trades on the NASDAQ under the ticker symbol "DRMA." Who are Dermata Therapeutics' major shareholders? Dermata Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (2.41%), Virtu Financial LLC (1.37%) and Citadel Advisors LLC (0.54%). How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Dermata Therapeutics' stock price today? One share of DRMA stock can currently be purchased for approximately $1.07. How much money does Dermata Therapeutics make? Dermata Therapeutics (NASDAQ:DRMA) has a market capitalization of $3.41 million. The company earns $-9,610,000.00 in net income (profit) each year or ($8.02) on an earnings per share basis. How can I contact Dermata Therapeutics? The official website for the company is www.dermatarx.com. The company can be reached via phone at 858-800-2543 or via email at sproehl@dermatarx.com. This page (NASDAQ:DRMA) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.